[Neuromyelitis optica spectrum disorder and pregnancy]
- PMID: 29383411
- DOI: 10.1007/s00115-018-0486-4
[Neuromyelitis optica spectrum disorder and pregnancy]
Abstract
Background: Neuromyelitis optica spectrum disorders (NMOSD) are autoimmune inflammatory diseases of the central nervous system that mainly affect women. In some of these patients NMOSD occurs during fertile age. For this reason, treating physicians may be confronted with questions concerning family planning, pregnancy and birth.
Objective: This study provides an overview on the influence of NMOSD on fertility, pregnancy complications and pregnancy outcome. The effect of pregnancy on NMOSD course and therapy options during pregnancy are discussed.
Material and methods: A search of the current literature was carried out using the PubMed database.
Results and conclusion: Animal studies have shown lower fertility rates in NMOSD; however, studies investigating fertility in NMOSD patients are lacking. Pregnancy in NMOSD patients are associated with an increase in postpartum disease activity and a higher grade of disability after pregnancy. Some studies showed higher risks of pregnancy complications e. g. spontaneous abortions and preeclampsia. With a few limitations, acute relapses during pregnancy can be treated with methylprednisolone and/or plasma exchange/immunoadsorption. Stopping or continuing immunosuppressive therapy with azathioprine or rituximab during pregnancy should be critically weighed considering previous and current disease activity. Therefore, a joint supervision by a specialized center is recommended, particularly in specific situations such as pregnancy.
Keywords: Fertility; Immunosuppressive therapy; Methylprednisolone; Postpartum disease activity; Pregnancy complications.
Similar articles
-
Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies.EPMA J. 2018 Aug 10;9(3):249-256. doi: 10.1007/s13167-018-0143-9. eCollection 2018 Sep. EPMA J. 2018. PMID: 30174761 Free PMC article. Review.
-
Effectiveness and safety of immunosuppressive therapy in neuromyelitis optica spectrum disorder during pregnancy.J Neurol Sci. 2017 Jun 15;377:72-76. doi: 10.1016/j.jns.2017.03.051. Epub 2017 Mar 31. J Neurol Sci. 2017. PMID: 28477712
-
Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management.Mult Scler. 2017 Dec;23(14):1808-1817. doi: 10.1177/1352458517740215. Mult Scler. 2017. PMID: 29154728 Review.
-
High risk of postpartum relapses in neuromyelitis optica spectrum disorder.Neurology. 2017 Nov 28;89(22):2238-2244. doi: 10.1212/WNL.0000000000004681. Epub 2017 Nov 1. Neurology. 2017. PMID: 29093070 Free PMC article.
-
Outcome of pregnancies after onset of the neuromyelitis optica spectrum disorder.Eur J Neurol. 2020 Aug;27(8):1546-1555. doi: 10.1111/ene.14274. Epub 2020 May 25. Eur J Neurol. 2020. PMID: 32320109
Cited by
-
Efficacy and safety of monoclonal antibodies in neuromyelitis optica spectrum disorders: A survival meta-analysis of randomized controlled trials.Adv Ophthalmol Pract Res. 2022 May 18;2(3):100064. doi: 10.1016/j.aopr.2022.100064. eCollection 2022 Nov-Dec. Adv Ophthalmol Pract Res. 2022. PMID: 37846287 Free PMC article. Review.
-
Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies.EPMA J. 2018 Aug 10;9(3):249-256. doi: 10.1007/s13167-018-0143-9. eCollection 2018 Sep. EPMA J. 2018. PMID: 30174761 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical